AGS-009 / CoImmune - LARVOL DELTA

Experimental lupus therapy from Argos in partnering talks after strong phase 1 (MedCityNews) - Argos released positive P1 clinical trial results for AGS-009 at the 2012 European League Against Rheumatism Congress (EULAR) in Berlin, Germany this week; Argos has been clear about its desire to work with a partner to develop AGS-009; While the phase 1 results are positive, it might not yet be enough to land a deal with a large pharmaceutical company; In their efforts to reduce risk, pharmas have been holding off on completing partnership deals until a drug candidate has progressed further along in clinical development; Argos said in securities filings it might start additional clinical studies on AGS-009 even if the company has not found a partner

P1 results • Lupus

Results of a randomized placebo controlled phase 1a study of AGS-009, a humanized anti-interferon- α monoclonal antibody in subjects with systemic lupus erythematosus (EULAR 2012) - P1a, N=25; Pharmacokinetic analysis showed that peak serum concentration of AGS-009 increased proportionally to the dose administered ranging from 1.59 x 102-6.82 x 105 ng/mL; Mean terminal half-life ranged from 270 to 489 hours across the dosing groups and was consistent with prior results obtained in non-human primates

P1 data • Lupus

Argos Therapeutics expands global patent protection (Argos Therapeutics) - Allowed claims cover use of AGS-009 to treat SLE, IDDM, or psoriasis; Patent issuing from application is expected to expire in 2026

Anticipated patent expiry • Patent • Immunology • Lupus

Results of a randomized placebo controlled phase IA study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus (EULAR 2012) - Presentation time: 09.06.2012; 10:15AM; Anticipated presentation at EULAR 2012

Anticipated P1 data • Immunology • Lupus

Argos Therapeutics: Annual Report 2013 (Argos Therapeutics) - "In July 2011, we completed enrollment in a phase 1a clinical trial of AGS-009, a monoclonal antibody, for the treatment of systemic lupus erythematosus, or lupus, a chronic and disabling autoimmune disorder. We have not conducted any further development following the completion of the trial. We do not plan to conduct further development of AGS-009 unless and until we receive third party or government funding."

Discontinued • Immunology • Lupus